Adult; Antibodies, Monoclonal/administration & dosage; Crohn Disease/drug therapy; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents/administration & dosage; Humans; Male; Retrospective Studies; Statistics as Topic; Time Factors; Treatment Outcome; Young Adult
Abstract :
[en] Background Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks. Aim We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling. Methods This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks). Results Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.). Conclusion In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Kopylov, U.
Mantzaris, G. J.
Katsanos, K. H.
Reenaers, Catherine ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Ellul, P.
Rahier, Jean-François
Israeli, E.
Lakatos, P. L.
Fiorino, G.
Cesarini, M.
Tsianos, E. V.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Hanauer S, Feagan B, Kichtenshtein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
Requeiro M, Siemanowski B, Kip K, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9.
Van Assche G, Vermeire S, Rutgeerts P,. Management of loss of response to anti-TNF drugs: change the dose or change the drug? J Crohn's Colitis 2008; 2: 348-51.
Magro F, Bastos R, Marques M, et al. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis 2008; 14: 432-4.
Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
Klotz U, Teml A, Schwab M,. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-60.
St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in Rheumatoid Arthritis. Arthritis Rheum 2002; 46: 1451-9.
Kaplan GG, Hur C, Korzenik J, Sands BE,. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-20.
Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab lies within the Fab fragment, but measurement of antibodies against the intact infliximab molecule shows superior clinical usefulness. Gut 2010 [Epub ahead of print].
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8. (Pubitemid 36204954)
Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.